Please try another search
For the six months ended 30 June 2017, Albany Molecular Research, Inc. revenues increased 49% to $336.8M. Net loss decreased 33% to $20.9M. Revenues reflect API segment increase of 61% to $205.4M, DDS segment increase of 22% to $60M, Drug Product segment increase of 10% to $55M, United States segment increase of 38% to $183.1M, Asia segment increase from $12.1M to $39.9M, Europe segment increase of 38% to $91.3M.
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Revenue | 172.93 | 163.82 | 191.32 | 152.74 |
Gross Profit | 41.22 | 41.04 | 38.74 | 29.25 |
Operating Income | -1.56 | 2.08 | -5.41 | -15.66 |
Net Income | -10.25 | -10.69 | -15.41 | -23.43 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Assets | 1242.37 | 1163.53 | 1209.65 | 1258.08 |
Total Liabilities | 925.35 | 866.73 | 910.67 | 920.09 |
Total Equity | 317.02 | 296.8 | 298.98 | 338 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | 8.52 | -6.41 | 26.64 | 5.23 |
Cash From Investing Activities | -10.64 | -4.06 | -193.2 | -181.78 |
Cash From Financing Activities | -11.88 | -7.24 | 170.84 | 172.01 |
Net Change in Cash | -9.77 | -16.81 | 2.66 | -4.59 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review